Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268325 | 0.88 | CYP4F2 (0.65) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL2021436 | 0.86 | CYP4F2 (0.67) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL28404067 | 0.86 | CYP4F2 (0.68) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL2993978 | 0.84 | CYP4F2 (0.71) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL22819335 | 0.84 | CYP4F2 (0.71) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL5306680 | 0.82 | CYP4F2 (0.62) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL669239 | 0.82 | CYP4F2 (0.57) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL6257314 | 0.80 | CYP4F2 (0.85) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL8160235 | 0.80 | CYP4F2 (0.60) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL6254544 | 0.80 | CYP4F2 (0.85) | CYP4F2CYP4A11MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260007768-A1 | CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12472261-B2 | Conjugated inhibitors of DNA damage response | PROLYNX LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-12364771-B2 | Conjugation linkers | PROLYNX LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-119970617-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | PROLYNX LLC (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4251150-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | Prolynx LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116635027-A | Prolonged release hydrogel conjugates of C-natriuretic peptides | 普罗林科斯有限责任公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220331437-A1 | CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE | PROLYNX LLC (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220280654-A1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2022-09-08 | — | — | US | disclosed |
| EP-0562440-B1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5491145-A | ANTIASTHMA, ANTI-PLATELET ACTIVATING FACTOR BRONCHOCONSTRICTION-INHIBITING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-5476848-A | Antihistamines | SANKYO COMPANY, LIMITED (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5407933-A | Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities and their use | SANKYO COMPANY, LIMITED (JP) | 1995-04-18 | — | — | US | disclosed |
| US-5389633-A | ANTIASTHMATIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0562439-A1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0562440-A1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| CN-1076450-A | Nitrogenous tetracyclic compound | SANKYO CO (JP) | 1993-09-22 | — | — | CN | disclosed |
| EP-0539164-A1 | Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use | Sankyo Company Limited (JP) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331437-A1 | CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE | DCLRE1A, DDB1, RAD50 | CYP4F2 3912/4885CYP4A11 4417/4885MEN1 2877/4885 |
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | NPPA, NPR1, NPR3 | CYP4F2 4571/4885CYP4A11 4470/4885MEN1 1286/4885 |
| US-20220280654-A1 | IMPROVED CONJUGATION LINKERS | DNPEP, SPPL2B, PTMS | CYP4F2 3296/4885CYP4A11 4514/4885MEN1 1057/4885 |
| US-20260007768-A1 | CONJUGATION LINKERS | OGFR, SLC43A1, ILK | CYP4F2 1044/4885CYP4A11 1010/4885MEN1 4764/4885 |
| US-12472261-B2 | Conjugated inhibitors of DNA damage response | DCLRE1A, DDB1, RAD50 | CYP4F2 3912/4885CYP4A11 4417/4885MEN1 2877/4885 |
| US-12364771-B2 | Conjugation linkers | DNPEP, FGB, VIP | CYP4F2 3234/4885CYP4A11 4429/4885MEN1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.